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Migration and invasion of cancer cellsLipocalin 2 (LCN2) is a poor prognostic factor in esophageal squamous cell carcinoma (ESCC), however its func-
tional roles andmolecular mechanisms of action remain to be clariﬁed. Here, we described the functions and sig-
naling pathways for LCN2 in ESCC. Overexpression of LCN2 in ESCC cells accelerated cell migration and invasion
in vitro, and promoted lungmetastasis in vivo. Blocking LCN2 expression inhibited its pro-oncogenic effect. Either
overexpression of LCN2 or treatment with recombinant human LCN2 protein enhanced the activation of MEK/
ERK pathway, which in turn increases endogenous LCN2 to increase MMP-9 activity. The decreased p-coﬁlin
and increased p-ERM induced by pERK1/2 cause the cytoskeleton F-actin rearrangement and alter the behavior
of ESCC cells mediated by LCN2. As a consequence, activation of MMP-9 and the rearrangement of F-actin throw
light on themechanisms for LCN2 in ESCC. These results imply that LCN2 promotes themigration and invasion of
ESCC cells through a novel positive feedback loop.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Lipocalin 2 (LCN2), also named Neutrophil gelatinase-associated
lipocalin (NGAL), amember of the lipocalin superfamily, is a 25 kDapro-
tein containing a signal peptide that enables it to be secreted and form
complexeswithmatrixmetalloproteinase-9 (MMP-9) through disulﬁde
bonds [1]. Similar to other lipocalin familymembers, LCN2 is involved in
diverse cellular processes, including the transport of small hydrophobic
molecules, protection of MMP-9 from proteolytic degradation, and
cell signaling [2–4]. Furthermore, LCN2 can tightly bind to bacterial
siderophore through a cell surface receptor, possibly serving as a potent
bacteriostatic agent by sequestering iron, regulating innate immunity
and protecting kidney epithelial cells from ischemia–reperfusion injury
[5–7].
Elevated LCN2 has also been observed in a wide spectrum of solid
tumor cells, including breast [8,9], colorectal [10,11], pancreatic [12],
ovarian [13], thyroid [14], bladder [15], kidney [16] and gastric cancers
[17], and gliomas [18], as well as esophageal squamous cell carcinomaslecular Biology for High Cancer
dical College, Shantou 515041,
.edu.cn (L.-Y. Xu).(ESCC) [19–21]. We previously found that LCN2 is overexpressed in
gastric carcinoma and its induction by 12-o-tetradecanoylphorbol-13-
acetate (TPA) is controlled by CCAAT/enhancer-binding protein beta
(C/EBPβ) [17]. Our recent studies show that LCN2 is upregulated in
ESCC tumor tissue and is signiﬁcantly correlated with cancer cell differ-
entiation and tumor invasion, and both elevated LCN2 and its receptor
are independent prognostic factors for ESCC [19–21]. However, the
functional role of LCN2 in cancer cells is not fully understood at present,
even sometimes there are controversial conclusions dropped from
different researches. LCN2 is able to facilitate gastrointestinal mucosal
regeneration by promoting cell motility and invasion and decreases
E-cadherin mediated cell–cell adhesion in colon cancer [10]. On the
other hand, it has been suggested that LCN2 reduces adhesion/invasion
partly by suppressing FAK activation and inhibits angiogenesis partly by
blocking VEGF production in pancreatic cancer cells [12]. Hanai et al.
also found LCN2 could convert 4T1-Ras-transformed mesenchymal
tumor cells to an epithelial phenotype, increase E-cadherin expression,
and suppress cell invasiveness in vitro and tumor growth and lung
metastases in vivo [22]. Moreover, ectopic expression of LCN2 in
human hepatocellular carcinoma cells signiﬁcantly inhibits the growth
of cancer cells in vitro and in vivo, reduces the invasive potential
of cells, and inhibits the expression of matrix metalloproteinase 2
(MMP-2) by the suppression of the JNK and PI3K/Akt pathways [23].
Although the function of LCN2 appears to be cell-type-dependent, the
2241Z.-P. Du et al. / Biochimica et Biophysica Acta 1853 (2015) 2240–2250exact role of LCN2 in ESCC cells remains to be elucidated. The purpose of
this study was to investigate the effects of LCN2 on the metastasis and
invasiveness of ESCC cells, and explore the underlying molecular
mechanisms.
2. Materials and methods
2.1. Cell culture and reagents
Several human ESCC cell lines were utilized in this study. The EC109
cell linewas purchased from the Chinese Academy of Science. SHEE and
SHEEC cell lines were isolated in our laboratory [24]. The EC8712 cell
line was provided by professor Sai-Wah Tsao (Department of Anatomy,Fig. 1. Anti-sense-mediated inhibition of LCN2 expression reduces migration and invasiveness o
carcinoma cell lines. SHEE is an immortalized esophageal epithelial cell line. SHEEC, EC8712, EC1
the internal control. (B) LCN2protein levels in anti-sense LCN2-expressing and control esophage
pcDNA-LCN2(−). (C) Migration assays for LCN2-anti-sense-expressing ESCC cells. (D) Invasion
experiment was carried out in triplicate, and results represent the Sum ± SD of three experimUniversity of Hong Kong, China), KYSE150 and KYSE180 cell lines were
generous gifts from Professor Dong Xie (Institute for Nutritional
Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy
of Sciences, China), and the TE3 cell line was a gift from Professor
Mingzhou Guo (Department of Gastroenterology & Hepatology,
Chinese PLA General Hospital, China). KYSE150, KYSE180 and TE3
cells were cultured in Roswell ParkMemorial Institute (RPMI) 1640me-
dium (HYCLONE, USA) with 10% fetal bovine serum and antibiotics
(100 U/ml penicillin and 100 mg/l streptomycin). EC109, EC8712,
SHEE and SHEEC cells were cultured in 199 medium (HYCLONE, USA)
with 10% new bovine serum and antibiotics (100 U/ml penicillin and
100 mg/l streptomycin). All cells were grown in a humidiﬁed 5% CO2
atmosphere at 37 °C. All these human ESCC cell lines in this studyf ESCC cells in vitro. (A)Western blot analysis of LCN2 protein levels in human esophageal
09, TE3, KYSE150 andKYSE180 are esophageal squamous carcinoma cell lines. β-actinwas
al carcinoma cells. Vector, cells transfectedwith pcDNA3.0; LCN2-AS, cells transfectedwith
assays for LCN2- anti-sense-expressing ESCC cells. For migration and invasion assay, each
ents.
Fig. 2. LCN2 overexpression promotes migration and invasiveness of ESCC cells in vitro. (A) LCN2 overexpression was detected by western blot. Vector, cells transfected with pcDNA3.0;
LCN2, cells transfected with pcDNA-LCN2(+). (B–C) Migration and invasion assays for LCN2-overexpressing ESCC cells. (D) Migration and invasiveness of ESCC cells promoted by the
stimulation of rhLCN2. For migration and invasion assay, each experiment was carried out in triplicate, and results represent the Sum± SD of three experiments.
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Fig. 3. LCN2 overexpression leads to increased lung metastasis and a shorter survival
time. (A) Lung metastasis observed in nude mice following tail vein injection with
stably-transfected EC109-LCN2 cells. H&E staining of lung tissue (left panel); a signiﬁcant
difference was found between nude mice injected with EC109-vector and EC109-LCN2
(right panel) cells. (B) Kaplan–Meier analysis showed LCN2 overexpression was negatively
correlated with nude mice survival (P= 0.007).
2243Z.-P. Du et al. / Biochimica et Biophysica Acta 1853 (2015) 2240–2250have been tested and authenticated by short tandem repeat (STR) DNA
proﬁling (Land Huagene Biosciences Co., LTD), and the authentication
results are shown in Fig. S1.
Recombinant human LCN2 protein (rhLCN2, 10222-H08H)was pur-
chased from Sino Biological Inc. of China. An Actin Reorganization Anti-
body Sample Kit (9967S), including antibodies against coﬁlin, p-coﬁlin
(Ser3) and p-ERM (T567), was from Cell Signaling Technology Inc.
(Danvers, MA). ERK (sc-94) and p-ERK1/2 (sc-7383) were from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies against beta-
actin (Sigma-Aldrich, St. Louis, USA, A2228) and LCN2 (R&D SYSTEMS,
INC. Minneapolis, USA, MAB1757) were also used. The following
secondary antibodies were used for western blot analysis: goat
anti-rabbit IgG-HRP (sc-2030, Santa Cruz), goat anti-mouse IgG-HRP
(sc-2005, Santa Cruz) and goat anti-rat IgG-HRP (sc-2032, Santa Cruz).
The MEK inhibitor U0126 was purchased from Promega (Madison,
USA, V1121).
2.2. Expression constructs
pcDNA-LCN2(+) and pcDNA-LCN2(−) plasmids were constructed
as follows: brieﬂy, the full-length coding region of human LCN2
(NM_005564.3) was ampliﬁed by RT-PCR from SHEEC cells using the
primers as follows: Forward: 5′-GTGGATCCTTCCTCGGCCCTGAAATC
ATG-3′, reverse: 5′-GGGAATTCTCAGCCGTCGATACACTGGTC-3′. The
PCR product was subcloned into the EcoRI site of pcDNA3.0(+) vector
(Invitrogen), resulting in constructs pcDNA-LCN2(+) (referred as
LCN2) and pcDNA-LCN2(−) (referred as LCN2-AS), the latter transcrib-
ing an antisense RNA to complement mature LCN2 mRNA. All relevant
regions of the ﬁnal constructs were conﬁrmed by DNA sequencing.
2.3. Establishment of stable LCN2-overexpressing or LCN2 knockdown
cell lines
EC109, KYSE150, KYSE180, TE3 and EC8712 cells were cultured in
basic medium condition and plated (2 × 105 cells/35-mm dish) 12 h
prior to transfection with SuperFect transfection reagent (QIAGEN,
USA) according to the manufacturer's recommendations. After 48 h,
cells were selected with the medium containing 400 μg/ml G418. The
plasmid pcDNA-LCN2(+) was transfected into EC109, KYSE150 or
KYSE180 cells, and referred to henceforth as the LCN2 group. The plas-
mid pcDNA-LCN2(−) was transfected into TE3 or EC8712 cells, and
referred to henceforth as the LCN2-AS group. Empty vector pcDNA3.0
was transfected into each cell line as a control, and referred to hence-
forth as the vector group. A single clone of transfected cells from each
group was passaged and used for all studies.
2.4. Western blotting
Western blotting was performed as described previously [20].
Whole-cell protein extracts were obtained by using RIPA buffer, and
then subjected to 12% SDS-PAGE and transferred onto a PVDF
membrane (Millipore, USA). Themembranes were blocked in 5% nonfat
milk for 1 h, followed by the addition of primary antibody for 2 h.
The membranes were then washed and incubated with secondary
antibody coupled to horseradish peroxidase for 2 h. Antigen-antibody
complexes were detected by Western blot luminol reagent (Santa
Cruz Biotechnology, USA). Photography and quantitative analyses of
related-immunoreactive bands were performed using a FluorChem™
IS-8900 (Alpha Innotech, USA).
2.5. Cell migration and invasion assays in vitro
Migration and invasion assays for stably-transfected cells were per-
formed using transwell chambers as described as we described before
[25]. For invasion assays, 1 × 105 cells were seeded onto the top cham-
ber of a 24-wellmatrigel-coatedmembranewith 8-μmpores (Millipore,USA), and the bottom chamber was ﬁlled with medium with 10%
fetal or new bovine serum (for the migration assay, cells were directly
plated on an uncoated chamber). After 24 h (invasion assays) or 48 h
(migration assays), the membranes were ﬁxed and stained by Giemsa
reagent. The cell numberswere quantiﬁed by counting 10 randomﬁelds
under a light microscope (400×). The mean value was calculated from
data obtained from 3 separate chambers. To investigate the effects of
rhLCN2 or U0126 on migration and invasion assays, cells were treated
with 10 μg/ml rhLCN2 or 40 μM/ml U0126 after plating in the top
chamber and quantiﬁed by the same methods.2.6. Tumor cell injection in SCID mice
Two age-matched groups of SCID mice (7 weeks-old) were injected
with EC109-vector cells or EC109-LCN2 cells (1.2 × 107) in 0.2 ml
serum-free 199 medium via the tail vein. These mice were raised
under pathogen-free (SPF) conditions. The use of animals complied
with the Guide for the Care and Use of Laboratory Animals (NIH
publication no. 86-23, revised 1985) and current Chinese law on the
protection of animals. Each group contained six SCID mice (three
males, three females). At 87 days after cell inoculation, ﬁve EC109-
vector cell-injected mice were still alive, while all of the EC109-LCN2
cell-injected mice were dead.
In a separate study, to examine the effect of LCN2 on tumormetasta-
sis in vivo, another two groups of SCIDmice (7weeks-old)were injected
with EC109-vector cells and EC109-LCN2 cells. These mice were kept
28 days under the same conditions until they were euthanized. Lungs
of the SCID mice were removed and stored in 4% paraformaldehyde
for examination by hematoxylin–eosin (H&E) staining.
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Stably-transfected KYSE150 cells were grown on slides in 24-well
plates, which were pretreated with 10 μg/ml ﬁbronectin at 37 °C for
2 h. When cells are 80%–90% conﬂuent, medium was aspirated and
cells were rinsed three times with 500 μl PBS for 5 min each time.Fig. 4. Signal pathwaymolecules involved in LCN2-overexpressing ESCC cells. (A) pERK1/2 was
NF-κB andMAPK signaling pathways, such as p65, p-p38 and p-JNK remained unchanged. Vect
was used as a loading control. (B) pERK1/2was elevated in serum-starved KYSE150 or KYSE180
and invasion is ERK-dependent. LCN2-overexpressing cells, pre-incubated for 24 h in RPMI 1640
in a migration assay (left panel) and invasion assay (right panel). U0126 abolished the enha
KYSE180 cells. Data are representative of three separate experiments.Then cells were ﬁxed in 4% formaldehyde for 10 min and washed as
described above. The coverslips were put on ice for less than 10 min
and washed again as described above. 30 μl rabbit monoclonal anti-
Phospho-Ezrin (Thr567)/Radixin (Thr564)/Moesin (Thr558) (41A3)
antibody (1:500, CST, #3149) was added to each coverslip and incubat-
ed overnight at 4 °C in the dark. After washing, coverslips were stainedelevated in ESCC cells overexpressing LCN2 and total ERK1/2 did not change. Molecules in
or, cells transfected with pcDNA3.0; LCN2, cells transfectedwith pcDNA-LCN2(+). β-actin
cells stimulated for 10min or 24 hwith 10 μg/ml rhLCN2. (C) LCN2-induced cellmigration
mediumwithout serum, were treatedwith or without theMEK inhibitor U0126 (40 μM),
ncement of migration and invasiveness by LCN2 overexpression in EC109, KYSE150 and
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Dylight 594-conjugated AfﬁniPure Donkey anti-rabbit IgG (H + L)
(Jackson, #99212) for 1 h. After staining with DAPI for 10 min, the
coverslips were mounted with antifade mounting medium (Beyotime,
China, #P0126) on slides, and cells were observed with a confocal
microscope (FV1000, OLYMPUS).Fig. 5. LCN2 overexpression mediates actin cytoskeleton rearrangement. (A) Coﬁlin, an actin di
decreased with unchanged total coﬁlin protein. The protein level of activated p-ERM (T567)
KYSE150-LCN2 cells were dramatic increased compared with the control. The stress ﬁber was
F-actin, especially in extended ﬁlopodia. Scale bar, 20 μm. (D) The number and length of ﬁlop
10 μm. (E–G) The per cell ﬁlopodia counts, length and length range were analyzed from three2.8. Live-cell imaging
Stably-transfected KYSE150 cells were plated in ﬁbronectin-coated
24-well plates. Cells were transiently transfected with the GFP-LifeAct
(kindly provided by Prof. Brian Stramer, University of Manchester, UK)
using Lipofectamine 2000 reagent (Invitrogen, USA). After 12 h, cellssassembly protein, was detected in LCN2-overexpressing ESCC cells. Inactive p-coﬁlin was
was also increased in both LCN2-elevated KYSE150 and KYSE180 cells. (B) Filopodia in
indicated by a white arrow. Scale bar, 10 μm. (C) Increased p-ERM also co-localized with
odia were greater in LCN2-overexpressing cells shown in a time-lapse series. Scale bar,
KYSE150-LCN2 or KYSE150-vector cells.
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allowed to attach for 1 h before live-cell imaging. The treated cells
were visualized using a confocal microscope (FV1000, OLYMPUS). We
recorded one frame per 1 min. Filopodia number and length were
measured and analyzed from two independent experiments using NIH
ImageJ software.
2.9. Real-time reverse transcription polymerase chain reaction
Total cellular RNA was extracted with Trizol reagent (Invitrogen)
from KYSE180 cells treated with 10 μg/ml rhLCN2 and reverse-
transcribed to cDNA using the Reverse Transcription System (Promega,
USA). Real-time RT-PCRwas carried out using the Rotor-Gene 6000 sys-
tem (Corbett Life Science, Australia) using SYBR®Premix Ex Taq™Fig. 6. A positive LCN2 feedback loop is mediated by the MEK/ERK signaling pathway. (A) LCN
rhLCN2. (B) LCN2mRNA levels in cells induced by rhLCN2 at different time points were analyze
tein levels and abolished the effect of LCN2 on ERK. These results show that U0126 blocked the
cells stimulated for 10 min or 24 h with 10 μg/ml rhLCN2 with or without U0126 (40 μM) pret(TaKaRa, Japan) according to the manufacturer's instruction. All PCRs
were done in triplicate. The absolute LCN2mRNA level was normalized
to β-actin.2.10. Statistical analysis
The differences in cell migration and invasiveness in vitro and the
number of lung metastases in the SCID mice were analyzed by the
Student's t-test. Lifespans of the mice were analyzed using the
Kaplan–Meier method. A two-tailed P-value less than 0.05 were con-
sidered statistically signiﬁcant. All statistical analyses were per-
formed using SPSS 13.0 for Windows software (SPSS INC., Chicago,
US).2 was elevated in KYSE150 or KYSE180 cells stimulated for 10 min or 24 h with 10 μg/ml
d by qRT-PCR. β-actin was the internal control. (C) U0126 reduced endogenous LCN2 pro-
LCN2 positive feedback loop involvingMEK/ERK. Cell lysates were obtained from KYSE180
reatment for 1 h. Changes in pERK1/2 and endogenous LCN2 protein levels were detected.
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3.1. LCN2 over-expression increases themigration and invasiveness of ESCC
cells in vitro
To study the expression pattern of the LCN2 in ESCC cell lines,we ini-
tially examined the LCN2 protein level in a panel of six ESCC cell lines
(Fig. 1A). Low LCN2 protein levels were observed in EC109, KYSE150
and KYSE180 cells, which were selected for LCN2 over-expression,
while the TE3 and EC8712 cell lines displayed high LCN2 protein levels
and were selected for LCN2 knockdown in subsequent function studies.
Since tumor cell motility is an important characteristic contributing to
metastatic tumor cell spread, to explore the roles of LCN2 in migration
and invasiveness, pcDNA-LCN2(−) or empty vector (pcDNA3.0) were
stably transfected into the TE3 and EC8712 cell lines. Decreased expres-
sion of LCN2 protein was conﬁrmed bywestern blotting (Fig. 1B). Then,
we evaluated the migration and invasiveness of the transfected cells
in vitro. As shown in Fig. 1C and D, the migration and invasiveness of
both LCN2-AS ESCC cell lines was signiﬁcantly lower than those of the
control group.
On the other hand, when pcDNA-LCN2(+) was stably transfected
into the EC109, KYSE150 and KYSE180 cell lines to over-express LCN2
protein (Fig. 2A), the migration and invasiveness of ESCC cells was
signiﬁcantly increased compared to empty vector-transfected cells
(Fig. 2B and C). Since LCN2 is a secreted protein, it was of interest to
understand the effects of the secreted LCN2 protein on ESCC cells.
Migration and invasion assays were also performed with KYSE150 and
KYSE180 cells that were stimulated by 10 μg/ml recombinant human
LCN2 protein (rhLCN2) after inoculating in transwell chambers.
Interestingly, migration and invasion of KYSE150 and KYSE180 cells
was also greatly enhanced after rhLCN2 stimulation (Fig. 2D).Fig. 7. Schematic representation of molecular mechanisms through which LCN2 promotes the
facilitate cancer cell migration and invasion, but also increases the level of pERK1/2, which in t
also increases p-ERM, but decreases p-coﬁlin, causing rearrangement of the actin cytoskelet
ERM, ezrin/radixin/moesin protein family.3.2. LCN2 overexpression promotes lung metastasis and decreases survival
in tumor-bearing mice
To explore the role of LCN2 in the progression of ESCC, EC109 cells
were stably transfected with pcDNA-LCN2(+) (EC109-LCN2) or
empty vector pcDNA3.0 (EC109-vector) (Fig. 2A). Then, both cell lines
were separately injected into SCID mice via the tail vein. The effect of
LCN2 on tumor metastasis to the lung was addressed by observing
metastatic colonizations on the lung surface, following H&E staining,
at 28 days after tumor cell injection (Fig. 3A). Lung colonization by
EC109-LCN2 cells was signiﬁcantly greater than EC109-vector cells,
suggesting that over-expression of LCN2 promotes cancer metastasis
in vivo (Fig. 3A).
Effect of LCN2 overexpression on the survival of the nude mice was
also analyzed. EC109-LCN2 and EC109-vector cells were injected into
SCID mice via tail veins. The investigation was suspended when all of
the EC109-LCN2 mice died, and then survival rates were evaluated
using Kaplan–Meier survival curves and the log-rank test. As shown in
Fig. 3B, the survival rate of LCN2-overexpressing cell-bearing mice was
signiﬁcantly lower than that of the control group (P= 0.007).
3.3. Increased LCN2 activates pERK1/2
There are several mechanisms for LCN2 involves in the metastasis
and invasion of cancer cells, including MMP-9 [4,20], E-cadherin [10],
and NF-κB [26]. To investigate whether overexpression of LCN2 altered
the status of MMP-9 in ESCC, the zymography analyseswere performed
and showed that the activity of MMP-9 in LCN2 over-expressing cells
was obviously elevated (Fig. S2), suggesting LCN2 could enhance
tumor cell metastasis and invasiveness through enhancing the activity
of MMP-9 in ESCC cells, which is consistent with the previous reports.invasiveness of ESCC cells by a positive feedback loop. LCN2 not only protects MMP-9 to
urn leads to the increase of LCN2 at both the mRNA and protein levels. Elevated pERK1/2
on to promote the migration and invasion of ESCC cells. LR, LCN2 receptor; CFL, coﬁlin;
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the E-cadherin protein level did not alter obviously after the treatment
of rhLCN2 (Fig. S3). These results indicated that some new mechanism
underlies LCN2 promotion of metastasis and invasion, except the
known protection of MMP-9 from degradation. To examine the impact
of LCN2 on other signaling pathways, ERK1/2, pERK1/2, NF-κB, p-p38,
p-JUN and p-AKT were also detected. Nevertheless, NF-κB, p-p38,
p-JUN and p-AKT did not change signiﬁcantly, suggesting that these
molecules did not involve in the LCN2 promotion of metastasis and in-
vasion in ESCC cell (Fig. 4A, Fig. S4). To our interest, the pERK1/2 level
was signiﬁcantly higher in LCN2-overexpression cells than that in the
control cells, while pERK1/2 was decreased in the cells in which LCN2
expression was blocked (Fig. 4A). Intriguingly, addition of 10 μg/ml
rhLCN2,whichpromoted ESCC cellmigration and invasion, also resulted
in the elevation of pERK1/2, with peak levels occurring at 24 h (Fig. 4B).
To determine whether LCN2-mediated ERK activation was essential
for cell migration and invasion, three LCN2-overexpressing cell lines
were treated with the MEK inhibitor U0126 after inoculating cells in a
transwell chamber. U0126 treatment completely abolished LCN2-
mediated cell migration and invasion (Fig. 4C).
3.4. LCN2 overexpression-mediated actin cytoskeleton rearrangement
It has been reported that MEK/ERK promotes dephosphorylation of
coﬁlin and subsequent the disassembly of stress ﬁbers by interrupting
the Rho-ROCK-LIMK cascade [27,28]. Coﬁlin, a small ubiquitous protein
(~19 kDa) that is able to bind to both G-actin and F-actin, is closely as-
sociatedwith actin cytoskeletal rearrangement and tumor invasion, and
which is inhibited by its phosphorylation (p-coﬁlin) [29]. It has previ-
ously been shown that ERK1/2 is upstream of ezrin/radixin/moesin
(ERM) protein family and enhances its activation (phospho-ERM,
p-ERM) [30]. The ERM protein family, which cross-links actin ﬁlaments
with plasma membrane proteins, is able to enhance the assembly of
stress ﬁbers and thus ﬁlolodia after its phosphorylation modiﬁcation
[31,32]. Based on these evidences, we proposed whether LCN2 promo-
tion of metastasis and invasion via the activation of ERK pathway,
which induces its downstream effectors to cause the rearrangement of
F-actin. Therefore, the protein levels of p-coﬁlin and p-ERM in these
cell lines were detected by western blotting. The results showed that
p-coﬁlin protein level was signiﬁcantly decreased, but p-ERM (T567)
was obviously increased after LCN2 overexpression (Fig. 5A). Inspired
by the change of p-coﬁlin and p-ERM after LCN2 was overexpressed,
we therefore examined the role of LCN2 in stress ﬁber and ﬁlopodia for-
mation. Using phalloidin staining, we found that stress ﬁber formation
was dispersed and suppressed in KYSE150-LCN2 cells. On the other
hand, ﬁlopodia in KYSE150-LCN2 cells were signiﬁcantly increased
comparedwith the control (Fig. 5B). Moreover, we found that the stress
ﬁbers in LCN2-overexpressing EC109 cells were more disordered than
the control, with F-actin cytoskeleton was radially rearranged in the
periphery of LCN2-overexpressing cells (Fig. S5). These results suggest
that upregulation of LCN2 inhibits stress ﬁber formation and enhances
ﬁlopodia extension. Since p-ERM is enhanced after LCN2 overexpres-
sion, we next performed immunoﬂuorescence staining experiments to
evaluate the subcellular localization of p-ERM. We found increased
p-ERM co-localization with F-actin, especially in the extended ﬁlopodia
(Fig. 5C).
To further conﬁrm our ﬁndings, we performed live-cell imaging
analyses for KYSE150-transfected cells to observe the dynamic activity
of ﬁlopodia. As shown in Fig. 5D, the number and length of ﬁlopodia
was more obvious in the LCN2-overexpressing cells in a time course.
The progression of extension and formation of ﬁlopodia is also shown
in Movie S1 and Movie S2 for LCN2-overexpressing KYSE150 cells and
its control, respectively. We also analyzed the per-cell ﬁlopodia counts,
length and length range from three KYSE150-transfected cells. The
results indicated that LCN2 overexpression leads to a greater number
of ﬁlopodia, and ﬁlopodia that are longer on average (Fig. 5E–G).3.5. ERK-mediated LCN2 regulations positive feedback
Because pERK1/2 was elevated after stimulation with rhLCN2
(Fig. 4B), we examined the impact of ERK signaling on the expression
of LCN2. To our surprise, the endogenous LCN2 protein level was in-
creased after stimulation with rhLCN2 protein in both KYSE150 and
KYSE180 cells (Fig. 6A). The expression pattern of LCN2 was similar to
the activation of pERK1/2, with levels of both peaking at 24 h. To test
whether this regulation occurred at the transcriptional level, we ana-
lyzed LCN2 mRNA levels by qRT-PCR. Consistently, the results showed
that at 10 min, 1 h and 24 h post-stimulation, the LCN2 mRNA level
was elevated 1.40-fold, 2.24-fold and 1.83-fold, respectively (Fig. 6B).
Analysis of the activity of the LCN2 promoter (−1431 to +81), in
stably-transfected KYSE150 cells, using a dual-luciferase reporter system,
also indicated that the promoter activity was higher in LCN2-
overexpressing cells than that in the control cells (Fig. S6). Moreover,
the MEK inhibitor U0126 could diminish the stimulation of endogenous
LCN2 protein and pERK1/2 in KYSE180 cells induced by rhLCN2 (Fig. 6C).
4. Discussion
LCN2, a small molecular weight secreted glycoprotein, is up-
regulated in a variety of cancers, including ESCC [8–21]. Recent studies
suggest that LCN2 is a key player in different cancer types [10,12,23].
However, its importance in the progression of cancers remains inconsis-
tent and puzzling. The data presented in our study suggest that an onco-
genic effect of LCN2 is as an enhancer of ESCC metastasis. This is
supported by at least two lines of experimental evidence. First, ectopic
expression of LCN2 in ESCC cell lines increased metastatic and invasive
ability both in vitro and in vivo. In contrast, blocking LCN2 in ESCC cell
lines with high endogenous LCN2 protein levels decreased the ability
to metastasize and invade in vitro. Second, treatment with recombinant
LCN2 enhanced the metastatic and invasive abilities of ESCC cell lines
with low endogenous LCN2 expression.
Our data is consistent with our previous report that overexpression
of LCN2 is associated with the tumor invasion depth in ESCC tissue
[20]. In accordance with our results, mounting evidence has demon-
strated that elevated LCN2 expression promotes the invasion and pro-
gression of tumors, such as breast cancer and colon cancer [10,11].
Conversely, several lines of evidence demonstrate that LCN2 is a
suppressor of cancer cell metastasis and invasion, such as pancreatic
cancer [12]. Two possibilities could explain this complex biological
phenomenon. One is the distinct molecular mechanisms of LCN2 in
different cell types. LCN2 has been reported to increase cell motility
and invasion by decreasing E-cadherin mediated cell–cell adhesion in
colon carcinoma cells [12]. But in our LCN2-overexpressing cell lines,
E-cadherin did not show the typical decrease following LCN2 overex-
pression (Fig. S2). A second possibility is the different activated signal-
ing pathway(s) involving LCN2. This is supported by a previous study
showing that the HER2/phosphoinositide 3-kinase/AKT/NF-κB signal
cascade induces LCN2 expression to facilitate breast tumorigenesis
and metastasis [26]. However, we show here that LCN2 expression is
largely dependent on the ERK1/2 pathway in ESCC.
Accumulated evidences suggest the importance role for ERK1/2 in
the regulation of cytoskeleton rearrangement through its downstream
effectors, such as coﬁlin and p-ERM [33,34]. Our results in this study
also suggested that ERK1/2 might be a hub for the role of LCN2 in
ESCC. Thus, we proposed that there is the positive feedback loop of
LCN2 in ESCC, whereby LCN2 acts as a tumorigenic effector by stimulat-
ing the MEK/ERK signaling pathway through its membrane receptor
(Fig. 7) [5,21,35]. In this instance, ectopic expression LCN2 activates
pERK1/2, which in turn increases endogenous LCN2. The elevated
LCN2 stabilized MMP-9 by forming heterodimer complexes to facilitate
motility and invasiveness of ESCC cells. On the other hand, the de-
creased of p-coﬁlin and increased p-ERM induced by pERK1/2 cause
the cytoskeleton F-actin rearrangement and alter the behavior of ESCC
2249Z.-P. Du et al. / Biochimica et Biophysica Acta 1853 (2015) 2240–2250cells mediated by LCN2. As a consequence, activation of MMP-9 and the
rearrangement of F-actin throw light on the role of LCN2 in promoting
migration and invasion in ESCC. To our knowledge, this is theﬁrst report
that LCN2 activates MEK/ERK signaling in a feedback loop in cancer.
Similar to our results, it has been reported the interaction of CTGF and
β-catenin-TCF/Lef form a positive feedback loop, which could contrib-
ute to the tumorigenicity of ESCC [36]. These results indicate that feed-
back loops widely exist and regulate the behavior of ESCC cells. LCN2
plays an important role in ESCC cell biology by promoting ESCC cell in-
vasion and metastasis, but evidence is still lacking about how it actives
MEK/ERK to mediate this positive feedback loop and other key biologi-
cal events in neoplastic progression.
In summary, our results suggest that LCN2 and MEK/ERK signaling
pathway form a positive feedback loop. LCN2 can activateMEK/ERK sig-
naling pathway and thus contribute to ESCC malignancy. Furthermore,
MEK/ERK signaling also positively regulates the expression of LCN2,
which further promotes the progression of ESCC. These ﬁndings not
only provide insight into the molecular mechanism underlying LCN2
in cancer development, but also expand the regulatory network of the
MEK/ERK-LCN2 signaling pathway in the development and progression
of ESCC.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.07.007.
Funding
This work was supported by grants from the National Natural
Science Foundation of China (No.81172264 and No.81472613), the
National High Technology Research and Development Program of China
(No.2012AA02A503 and No.2012AA02A209), and the Natural Science
Foundation of China-Guangdong Joint Fund (No.U1301227), the Science
and Technology Program of Guangdong (2011B060300025). The authors
have declared that no competing interests exist.
Conﬂict of interest
The authors report no conﬂict of interest.
Acknowledgments
We thank Dr. Stanley Lin (Shantou University Medical College) for
proofreading the manuscript and Mrs. Yan-Fei Xie (Shantou University
Medical College) for her kind assistance with the animal experiments.
References
[1] D.R. Flower, The lipocalin protein family: structure and function, Biochem. J. 318
(1996) 1–14.
[2] L. Kjeldsen, A.H. Johnsen, H. Sengeløv, N. Borregaard, Isolation and primary structure
of NGAL, a novel protein associated with human neutrophil gelatinase, J. Biol. Chem.
268 (1993) 10425–10432.
[3] D.R. Flower, Experimentally determined lipocalin structures, Biochim. Biophys. Acta
1482 (2000) 46–56.
[4] L. Yan, N. Borregaard, L. Kjeldsen, M.A. Moses, The high molecular weight urinary
matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and
neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity
by NGAL, J. Biol. Chem. 276 (2001) 37258–37265.
[5] V. Hvidberg, C. Jacobsen, R.K. Strong, J.B. Cowland, S.K. Moestrup, N. Borregaard, The
endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-
associated lipocalin with high afﬁnity and mediates its cellular uptake, FEBS Lett.
579 (2005) 773–777.
[6] J. Yang, D. Goetz, J.Y. Li, W. Wang, K. Mori, D. Setlik, T. Du, H. Erdjument-Bromage, P.
Tempst, R. Strong, J. Barasch, An iron delivery pathway mediated by a lipocalin, Mol.
Cell 10 (2002) 1045–1056.
[7] N. Paragas, A. Qiu, M. Hollmen, T.L. Nickolas, P. Devarajan, J. Barasch, NGAL-
siderocalin in kidney disease, Biochim. Biophys. Acta 1823 (2012) 1451–1458.
[8] A.S.Wenners, K. Mehta, S. Loibl, H. Park, B. Mueller, N. Arnold, S. Hamann, J.Weimer, B.
Ataseven, S. Darb-Esfahani, C. Schem, C. Mundhenke, F. Khandan, C. Thomssen, W.
Jonat, H.J. Holzhausen, G. von Minckwitz, C. Denkert, M. Bauer, Neutrophil gelatinase-
associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clin-
ical outcome in primary human breast cancer, PLoS One 7 (2012) e45826.[9] J. Yang, D.R. Bielenberg, S.J. Rodig, R. Doiron, M.C. Clifton, A.L. Kung, R.K. Strong, D.
Zurakowski, M.A. Moses, Lipocalin 2 promotes breast cancer progression, Proc.
Natl. Acad. Sci. U. S. A. 106 (2009) 3913–3918.
[10] L. Hu,W. Hittelman, T. Lu, P. Ji, R. Arlinghaus, I. Shmulevich, S.R. Hamilton,W. Zhang,
NGAL decreases E-cadherin mediated cell–cell adhesion and increases cell motility
and invasion through Rac1 in colon carcinoma cells, Lab. Investig. 89 (2009)
531–548.
[11] J. Martí, J. Fuster, A.M. Solà, G. Hotter, R. Molina, A. Pelegrina, J. Ferrer, R. Deulofeu, C.
Fondevila, J.C. García-Valdecasas, Prognostic value of serum neutrophil gelatinase-
associated lipocalin in metastatic and nonmetastatic colorectal cancer, World J.
Surg. 37 (2013) 1103–1109.
[12] Z. Tong, A.B. Kunnumakkara, H. Wang, Y. Matsuo, P. Diagaradjane, K.B. Harikumar, V.
Ramachandran, B. Sung, A. Chakraborty, R.S. Bresalier, C. Logsdon, B.B. Aggarwal, S.
Krishnan, S. Guha, Neutrophil gelatinase-associated lipocalin: a novel suppress or
of invasion and angiogenesis in pancreatic cancer, Cancer Res. 68 (2008)
6100–6108.
[13] R. Lim, N. Ahmed, N. Borregaard, C. Riley, R. Wafai, E.W. Thompson, M.A. Quinn, G.E.
Rice, Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomark-
er for ovarian cancer: NGAL is associated with epidermal growth factor-induced
epithelio-mesenchymal transition, Int. J. Cancer 120 (2007) 2426–2434.
[14] A. Iannetti, F. Paciﬁco, R. Acquaviva, A. Lavorgna, E. Crescenzi, C. Vascotto, G. Tell,
A.M. Salzano, A. Scaloni, E. Vuttariello, G. Chiappetta, S. Formisano, A. Leonardi,
The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated
gene, is a survival factor for thyroid neoplastic cells, Proc. Natl. Acad. Sci. U. S. A.
105 (2008) 14058–14063.
[15] M.A. Mohammed, M.F. Seleim, M.S. Abdalla, H.M. Sharada, A.H. Abdel Wahab, Uri-
nary high molecular weight matrix metalloproteinases as non-invasive biomarker
for detection of bladder cancer, BMC Urol. 13 (2013) 25.
[16] A.D.I. Carlo, Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix
metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of
patients with kidney tumors, Oncol. Lett. 5 (2013) 1677–1681.
[17] Z.P. Du, H.M. Yuan, B.L. Wu, J.X. Chang, Z. Lv, J. Shen, J.Y. Wu, H.B. Chen, E.M. Li, L.Y.
Xu, Neutrophil gelatinase-associated lipocalin in gastric carcinoma cells and its in-
duction by TPA are controlled by C/EBPβ, Biochem. Cell Biol. 89 (2011) 314–324.
[18] M.F. Liu, T. Jin, J.H. Shen, Z.Y. Shen, Z.C. Zheng, Z.L. Zhang, L.Y. Xu, E.M. Li, H.X. Xu,
NGAL and NGALR are frequently overexpressed in human gliomas and are associat-
ed with clinical prognosis, J. Neurooncol. 104 (2011) 119–127.
[19] L.Y. Xu, E.M. Li, H.Q. Xiong, W.J. Cai, Z.Y. Shen, Study of neutrophil gelatinase-
associated lipocalin (NGAL) gene overexpression in the progress of malignant
transformation of human immortalized esophageal epithelial cell, Prog. Biochem.
Biophys. 28 (2001) 839–843.
[20] H. Zhang, L. Xu, D. Xiao, J. Xie, H. Zeng, Z. Wang, X. Zhang, Y. Niu, Z. Shen, J. Shen, X.
Wu, E. Li, Up regulation of neutrophil gelatinase associated lipocalin in oesophageal
squamous cell carcinoma: signiﬁcant correlation with cell differentiation and tumour
invasion, J. Clin. Pathol. 60 (2007) 555–561.
[21] Z.P. Du, Z. Lv, B.L. Wu, Z.Y. Wu, J.H. Shen, J.Y. Wu, X.E. Xu, Q. Huang, J. Shen, H.B.
Chen, E.M. Li, L.Y. Xu, Neutrophil gelatinase-associated lipocalin and its receptor:
independent prognostic factors of oesophageal squamous cell carcinoma, J. Clin.
Pathol. 64 (2011) 69–74.
[22] J. Hanai, T. Mammoto, P. Seth, K. Mori, S.A. Karumanchi, J. Barasch, V.P. Sukhatme,
Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells,
J. Biol. Chem. 280 (2005) 13641–13647.
[23] E.K. Lee, H.J. Kim, K.J. Lee, H.J. Lee, J.S. Lee, D.G. Kim, S.W. Hong, Y. Yoon, J.S. Kim,
Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by
lipocalin 2 through blockade of JNK and PI3K/Akt signaling, Int. J. Oncol. 38 (2011)
325–333.
[24] Z. Shen, J. Shen, W. Cai, J. Chen, Y. Zeng, Malignant transformation of the immor-
talized esophageal epithelial cells, Zhonghua Zhong Liu Za Zhi 24 (2002)
107–109.
[25] J.J. Xie, L.Y. Xu, J.Y. Wu, Z.Y. Shen, Q. Zhao, Z.P. Du, Z. Lv, W. Gu, F. Pan, X.E. Xu, D. Xie,
E.M. Li, Involvement of CYR61 and CTGF in the fascin-mediated proliferation and in-
vasiveness of esophageal squamous cell carcinomas cells, Am. J. Pathol. 176 (2010)
939–951.
[26] X. Leng, T. Ding, H. Lin, Y. Wang, L. Hu, J. Hu, B. Feig, W. Zhang, L. Pusztai, W.F.
Symmans, Y.Wu, R.B. Arlinghaus, Inhibition of lipocalin 2 impairs breast tumorigen-
esis and metastasis, Cancer Res. 69 (2009) 8579–8584.
[27] G. Pawlak, D.M. Helfman, Post-transcriptional down-regulation of ROCKI/Rho-
kinase through an MEK-dependent pathway leads to cytoskeleton disruption in
Ras-transformed ﬁbroblasts, Mol. Biol. Cell 13 (2002) 336–347.
[28] R.M. Klein, L.S. Spofford, E.V. Abel, A. Ortiz, A.E. Aplin, B-RAF regulation of Rnd3 par-
ticipates in actin cytoskeletal and focal adhesion organization, Mol. Biol. Cell 19
(2008) 498–508.
[29] K. Mizuno, Signaling mechanisms and functional roles of coﬁlin phosphorylation
and dephosphorylation, Cell. Signal. 25 (2013) 457–469.
[30] A. Darmellah, A. Rayah, R. Auger, M.H. Cuif, M. Prigent, M. Arpin, A. Alcover, C.
Delarasse, J.M. Kanellopoulos, Ezrin/radixin/moesin are required for the purinergic
P2X7 receptor (P2X7R)-dependent processing of the amyloid precursor protein,
J. Biol. Chem. 287 (2012) 34583–34595.
[31] L. Parisiadou, C. Xie, H.J. Cho, X. Lin, X.L. Gu, C.X. Long, E. Lobbestael, V. Baekelandt,
J.M. Taymans, L. Sun, H. Cai, Phosphorylation of ezrin/radixin/moesin proteins by
LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogen-
esis, J. Neurosci. 29 (2009) 13971–13980.
[32] Y.Y. Li, C.X. Zhou, Y. Gao, Snail regulates the motility of oral cancer cells via RhoA/
Cdc42/p-ERM pathway, Biochem. Biophys. Res. Commun. 452 (2014) 490–496.
[33] A.K. Pullikuth, A.D. Catling, Scaffold mediated regulation of MAPK signaling and cy-
toskeletal dynamics: a perspective, Cell. Signal. 19 (2007) 1621–1632.
2250 Z.-P. Du et al. / Biochimica et Biophysica Acta 1853 (2015) 2240–2250[34] G.H. Wabnitz, G. Nebl, M. Klemke, A.J. Schröder, Y. Samstag, Phosphatidylinositol
3-kinase functions as a Ras effector in the signaling cascade that regulates dephos-
phorylation of the actin-remodeling protein coﬁlin after costimulation of untrans-
formed human T lymphocytes, J. Immunol. 176 (2006) 1668–1674.
[35] W.K. Fang, L.Y. Xu, X.F. Lu, L.D. Liao, W.J. Cai, Z.Y. Shen, E.M. Li, A novel alternative
spliced variant of neutrophil gelatinase-associated lipocalin receptor in oesophageal
carcinoma cells, Biochem. J. 403 (2007) 297–303.[36] Y.Z. Deng, P.P. Chen, Y. Wang, D. Yin, H.P. Koefﬂer, B. Li, X.J. Tong, D. Xie, Connective
tissue growth factor is overexpressed in esophageal squamous cell carcinoma and
promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling, J. Biol.
Chem. 282 (2007) 36571–36581.
